These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 28109295

  • 21. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S, Patel S, Crowe S, von Eynatten M.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Oct; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 24. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
    Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, Forst T.
    Cardiovasc Diabetol; 2013 Apr 08; 12():59. PubMed ID: 23565740
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, Izumoto T, Ning G.
    J Diabetes; 2016 Mar 08; 8(2):229-37. PubMed ID: 25753488
    [Abstract] [Full Text] [Related]

  • 26. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N, CARMELINA Investigators.
    Circulation; 2019 Jan 15; 139(3):351-361. PubMed ID: 30586723
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
    Christensen AS, Hædersdal S, Støy J, Storgaard H, Kampmann U, Forman JL, Seghieri M, Holst JJ, Hansen T, Knop FK, Vilsbøll T.
    Diabetes Care; 2020 Sep 15; 43(9):2025-2033. PubMed ID: 32661107
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
    Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE.
    Diabetes Obes Metab; 2021 Feb 15; 23(2):569-580. PubMed ID: 33185002
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2014 May 15; 16(5):418-25. PubMed ID: 24205974
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.
    Diabetes Obes Metab; 2008 Nov 15; 10(11):1047-56. PubMed ID: 18284434
    [Abstract] [Full Text] [Related]

  • 34. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 15; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May 15; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
    McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, von Eynatten M, Woerle HJ.
    Diab Vasc Dis Res; 2014 Jan 15; 11(1):34-40. PubMed ID: 24169807
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME, Puppala VK, Suboc TM, Malik M, Branum A, Signorelli K, Wang J, Ying R, Tanner MJ, Tyagi S.
    Vasc Med; 2017 Jun 15; 22(3):189-196. PubMed ID: 28145158
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.